Headlines Drug-Delivery 
European Pharmaceutical Review
APRIL 14, 2023
Oligonucleotide therapeutics represent a relatively novel class of drug, with the potential to modulate drug targets that were previously considered intractable, and with the benefit of fast clinical development times. Small interfering RNA (siRNA) were one of the most preferred drug delivery methods. The answers?
pharmaphorum
NOVEMBER 24, 2022
Two years ago, the EMA proposed a set of recommendations to unlock the potential of big data for public health, headlined by the creation of a platform to access and analyse healthcare data from across the bloc. With the first data partners on board, the regulator can now move ahead with the start of its first studies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 12, 2022
Prior to selling drugs or medical products in any country, pharmaceutical companies must prove compliance and gain the regulatory approval required by the country in which the goods will be distributed in. In fact, the FDA cited data as the cause of 79% of Drug Warning Letters over the last five years.
pharmaphorum
DECEMBER 24, 2020
The rapid digitalisation of life during COVID-19’s acute phase also had a huge impact on healthcare delivery. The year began with Exscientia moving the world’s first AI-created drug into clinical trials in January and there were also signs of the technology’s potential in drug pricing and spotting COVID-19 in chest x-rays.
Quality Matters
APRIL 20, 2023
While drug makers rely on USP standards for the clarity they provide on product quality specifications, regulators also look for manufacturer adherence to USP standards to indicate no additional validation of quality testing methods may be needed. In fact, USP documentary standards are recognized in U.S.
pharmaphorum
FEBRUARY 17, 2021
At JP Morgan’s annual health care conference in January 2018, Dimon hosted a private dinner for about 25 top executives from pharmaceutical companies and advocated for lower drug prices. He told his guests, “We are not happy with healthcare costs and want to help.” Costs Remain a Problem.’. Cost” is not the problem.
Putting Patients First Blog
MARCH 4, 2024
The CGDP has played a crucial role in helping to alleviate the financial burden on Medicare beneficiaries by reducing out-of-pocket (OOP) costs for prescription drugs. Part D Risk Sharing The NHC recognizes CMS’ ongoing efforts in risk sharing to mitigate financial risks faced by Part D sponsors due to unforeseen drug expenses.
Expert insights. Personalized for you.
94 
Let's personalize your content